With respect to clinical outcomes, the KDM6A mutation was associated with shorter relapse-free survival, with a 2-year RFS of 60.1% for the wild-type group versus 34.7% for the mutation group (p = 0.016) in univariable analyses of 1676 consecutive patients with AML achieving CR/CRi (Figure 3A). Here, KDM6A is linked to acute myeloid leukemia.